These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17846268)

  • 1. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
    Barkhof F; Polman CH; Radue EW; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Poppe P; de Vos M; Lasri F; Bauer L; Dahms S; Wagner K; Pohl C; Sandbrink R
    Arch Neurol; 2007 Sep; 64(9):1292-8. PubMed ID: 17846268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
    Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
    Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
    Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Bauer L; Dahms S; Lanius V; Pohl C; Sandbrink R;
    Lancet; 2007 Aug; 370(9585):389-97. PubMed ID: 17679016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
    Panitch H; Miller A; Paty D; Weinshenker B;
    Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
    Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
    Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
    De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
    Kappos L; Polman CH; Freedman MS; Edan G; Hartung HP; Miller DH; Montalban X; Barkhof F; Bauer L; Jakobs P; Pohl C; Sandbrink R
    Neurology; 2006 Oct; 67(7):1242-9. PubMed ID: 16914693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.
    Miller DH; Molyneux PD; Barker GJ; MacManus DG; Moseley IF; Wagner K
    Ann Neurol; 1999 Dec; 46(6):850-9. PubMed ID: 10589537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
    Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
    N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.
    Polman C; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Selmaj K; Uitdehaag BM; Dahms S; Bauer L; Pohl C; Sandbrink R;
    J Neurol; 2008 Apr; 255(4):480-7. PubMed ID: 18004635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
    Comi G; Filippi M; Barkhof F; Durelli L; Edan G; Fernández O; Hartung H; Seeldrayers P; Sørensen PS; Rovaris M; Martinelli V; Hommes OR;
    Lancet; 2001 May; 357(9268):1576-82. PubMed ID: 11377645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
    Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
    Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-β-1b: a review of its use in multiple sclerosis.
    Plosker GL
    CNS Drugs; 2011 Jan; 25(1):67-88. PubMed ID: 21128695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-beta-1b: in newly emerging multiple sclerosis.
    McKeage K
    CNS Drugs; 2008; 22(9):787-92. PubMed ID: 18698876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.
    Soilu-Hänninen M; Aivo J; Lindström BM; Elovaara I; Sumelahti ML; Färkkilä M; Tienari P; Atula S; Sarasoja T; Herrala L; Keskinarkaus I; Kruger J; Kallio T; Rocca MA; Filippi M
    J Neurol Neurosurg Psychiatry; 2012 May; 83(5):565-71. PubMed ID: 22362918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
    Torkildsen O; Wergeland S; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Lilleås F; Pedersen T; Bjørnarå B; Dalene F; Kleveland G; Schepel J; Olsen IC; Myhr KM
    Arch Neurol; 2012 Aug; 69(8):1044-51. PubMed ID: 22507886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
    Edan G; Kappos L; Montalbán X; Polman CH; Freedman MS; Hartung HP; Miller D; Barkhof F; Herrmann J; Lanius V; Stemper B; Pohl C; Sandbrink R; Pleimes D;
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1183-9. PubMed ID: 24218527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.